BioFM Executive Board members and bioXclusters plus partners sign the China Gateway


Leave a comment

bioXclusters plus SMEs will benefit from a Chinese Gateway through Fenglin Group

This Monday, May 15th, representatives from bioXclusters plus and Fenglin Group signed a Gateway Agreement to offer free services and guidance for SMEs in their operations in China. Services will include assistance in market access, private investment, clinical trials and soft landing packages.  Continue reading

Advertisements


Leave a comment

Updated information about the mission to Japan (Oct. 9th – 14th, 2016)

The European Strategic Cluster Partnership alliance on Personalised Healthcare, bioXclusters plus, which joins together four leading European Bioclusters –BiocatBioMBioPmed and Lyonbiopole –, has organized a trade mission that will be heading to Japan this October. This visit is organised in cooperation with the EU-Japan Centre. The “Biotech Cluster SME Mission” will take place from 9th to 14th October 2016. Continue reading


1 Comment

bioXclusters partners take part in the Mission to Brazil headed by the European Commission

From 10th to 12th September 2013, the European Commission travelled to Brazil with a selection of 9 European, life science clusters and four SMEs. The mission’s objective was to foster bilateral exchanges at different levels between European and Brazilian partners. To this end, the mission was organised around the BioPartnering Latin America event. Continue reading


Leave a comment

FierceBiotech Special Report: China’s Rise Drives Investment in Biotech Drugs

Until recently, the history of the pharmaceutical industry in China was more about imitation than innovation.

According to a report by London-based market researcher Scrip Intelligence, approximately 40% of biotech sales in China come from biosimilars. This would explain why the market for biologics in China has been growing at a rate of more than 25% a year, while total sales of biotech drugs are still only $1.5 billion a year.  Read more